Replies to post #86993 on Biotech Values

[zigzagman]

Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin’s Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods:

http://ash.confex.com/ash/2009/webprogram/Paper25134.html

This information is a bit too technical for me...Did it pass Phase III with flying colors?...Any comments anyone?...TIA

If you missed yesterday's Analyst Conference, here's a link to it:

http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-EventDetails&EventId=2562799